小肾肿瘤的冷冻消融治疗

顾晓; WONG Carson

小肾肿瘤的冷冻消融治疗

顾晓^1,2, ,,
WONG Carson²

- 1. 扬州大学第一临床医学院泌尿外科(江苏扬州, 225001);
- 2. 美国俄克拉荷马大学医学中心泌尿外科

详细信息

通讯作者: 顾晓,E-mail:guxiao222@hotmail.com

中图分类号: R737.11

收稿日期: 2012-06-14

Cryoablation for small renal masses

GU Xiao^1,2, ,,
WONG Carson²

- 1. Department of Urology, First Clinical Medical College at Yangzhou University, Yangzhou, 225001, China;
- 2. Department of Urology, University of Oklahoma Medical Center

More Information

Corresponding author: GU Xiao, E-mail: guxiao222@hotmail.com

Received Date: 14 June 2012

摘要

摘要: 目的：回顾分析小肾肿瘤冷冻消融治疗的临床资料并总结经验。方法：2004年8月~2010年11月行腹腔镜下（腹腔镜组，n=7）或经皮穿刺（经皮组，n=24）冷冻消融治疗小肾肿瘤患者30例（31个肿瘤）。31个肿瘤中7个位于肾上极，12个位于肾中极，12个位于肾下极。冷冻治疗前均行肿瘤穿刺活检病理检查，术后定期随访。结果：平均手术时间腹腔镜组（142.1±32.9）min明显长于经皮组（103.8±29.9）min，差异有统计学意义（P=0.009）。中位出血量腹腔镜组为55 ml明显多于经皮组的5 ml，差异有统计学意义（P<0.001）。病理结果示19个（61.3%）肾细胞癌，4个（12.9%）嗜酸细胞瘤，5个（16.1%）良性肿瘤，3个（9.7%）穿刺标本中未见肿瘤组织。随访3~60（19.2±16.1）个月，术前平均血肌酐浓度141.5μmol/L与术后3个月复查浓度176.8 μmol/L差异无统计学意义意义（P=0.212）。1例（3.2%）患者术后出现肉眼血尿，1例（3.2%）肾细胞癌患者术后6个月复发。结论：冷冻消融是治疗小肾肿瘤安全有效的方法，适用于高危患者。
- 肾肿瘤 /
- 冷冻外科治疗 /
- 腹腔镜,经皮穿刺
Abstract: Objective: Review our experience with percutaneous and laparoscopic cryoablation for treating small renal masses. Method: We retrospectively analyzed renal cryoablation procedures performed between August 2004 and November 2010. 30 consecutive patients underwent laparoscopic (laparoscopy group, n=7) or percutaneous (percutaneous group, n=24) cryoablation for 31 tumors. 7, 12 and 12 tumors were located in upper pole, mid pole and lower pole, respectively. Biopsy was taken before cryoablation procedure started. Patients were followed up regularly. Result: Seven tumors were treated by laparoscopic cryoablation and the remaining 24 were treated by percutaneous cryoablation, mean operative time were significantly different (142.1±32.9 vs. 103.8±29.9 mins, P=0.009). Median estimated blood loss in laparoscopic group was significantly greater than in percutaneous group (55 vs 5ml, P<0.001). Pathologic results showed 19(61.3%) of renal cell carcinoma, 4(12.9%) of oncocytoma, 5(16.1%) of benign tumors and 3(9.7%) of no tumor tissue. Mean follow up interval was 19.2±16.1 (3-60) months. There was no significant difference in serum creatinine level between preoperative and 3 months postoperative (141.5 vs 176.8μmol/L, P=0.212). 1(3.2%) patient had post-operative gross hematuria and 1(3.2%) patient was found recurrence 6 months after cryoablation. Conclusion: Cryoablation is a safe and effective option for treating small renal mass, feasible for high risk patients with comorbidity.
- renal mass /
- cryotherapy /
- laparoscopy,percutaneous

HTML全文

参考文献(15)

[1]	BERGER A, KAMOI K, GILL I S, et al. Cryoablation for renal tumors:current status[J]. Curr Opin Urol, 2009, 19:138-142.
[2]	CHAWLA S N, CRISPEN P L, HANLON A L, et al. The natural history of observed enhancing renal masses:meta-analysis and review of the world literature[J]. J Urol, 2006,175:425-431.
[3]	UCHIDA M, IMAIDE Y, SUGIMOTO K, et al. Percutaneous cryosurgery for renal tumours[J]. Br J Urol, 1995,75:132-136.
[4]	CAVIEZEL A, TERRAZ S, SCHMIDLIN F, et al. Percutaneous cryoablation of small kidney tumours under magnetic resonance imaging guidance:medium-term follow-up[J]. Scand J Urol Nephrol, 2008, 42:412-416.
[5]	ARON M, KAMOI K, REMER E, et al. Laparoscopic renal cryoablation:8-year, single surgeon outcomes[J]. J Urol, 2010; 183:889-895.
[6]	DERWEESH I H, MALCOLM J B, DIBLASIO C J, et al. Single center comparison of laparoscopic cryoablation and CT-guided percutaneous cryoablation for renal tumors[J]. J Endourol, 2008, 22:2461-2467.
[7]	MALCOLM J B, BERRY T T, WILLIAMS M B, et al. Single center experience with percutaneous and laparoscopic cryoablation of small renal masses[J]. J Endourol, 2009,23:907-911.
[8]	VOLPE A, PANZARELLA T, RENDON R A, et al. The natural history of incidentally detected small renal masses[J]. Cancer, 2004, 100:738-745.
[9]	庄乾元, 曾晓勇. 肾脏小肿块的治疗选择[J]. 现代泌尿生殖肿瘤杂志,2009, 1(5):257-259.
[10]	KUNKLE D A, EGLESTON B L, UZZO R G. Excise, ablate or observe:the small renal mass dilemma——a meta-analysis and review[J]. J Urol, 2008, 179:1227-1233.
[11]	WOOLLEY M L, SCHULSINGER D A, DURAND D B, et al. Effect of freezing parameters (freeze cycle and thaw process) on tissue destruction following renal cryoablation[J]. J Endourol, 2002, 16:519-522.
[12]	AUGE B K, SANTA-CRUZ R W, POLASCIK T J. Effect of freeze time during renal cryoablation:a swine model[J]. J Endourol, 2006, 20:1101-1105.
[13]	YOUNG J L, CLAYMAN R V. Cryoprobe isotherms:a caveat and review[J]. J Endourol, 2010, 24:673-676.
[14]	MATIN S F, AHRAR K, CADEDDU J A, et al. Residual and recurrent disease following renal energy ablative therapy:a multi-institutional study[J]. J Urol, 2006, 176:1973-1977.
[15]	ATWELL T D, FARRELL M A, LEIBOVICH B C, et al. Percutaneous renal cryoablation:experience treating 115 tumors[J]. J Urol, 2008, 179:2136-2140.